<DOC>
	<DOCNO>NCT01830530</DOCNO>
	<brief_summary>This study aim assess efficacy combine treatment two antihypertensive agent ( telmisartan nifedipine ) subject mild hypertension expose high altitude .</brief_summary>
	<brief_title>HIGH Altitude CArdiovascular REsearch ANDES</brief_title>
	<detailed_description>This parallel group , prospective , double-blind , placebo control randomized trial , compare effect combination two antihypertensive agent ( telmisartan/nifedipine ) placebo hypertensive subject expose high altitude . The principal objective : 1. ass response BP high altitude exposure hypertensive subject reside sea level 2 . To assess efficacy safety combination telmisartan 80 mg nifedipine GITS 30 mg prevent possible excessive BP increase hypertensive subject expose high altitude . The following data collect study different step : - Clinical history - Symptoms adverse event questionnaire - Conventional BP heart rate ( HR ) measurement - seat measurement validate oscillometric device perform least 5 minute rest non-dominant arm ; two measurement perform 1-2 minute apart average used analysis - Vital sign : respiratory rate - measure manually 60 second body height weight , waist circumference blood oxygen saturation ( SpO2 ) - Lake Louise Score - 24 h ambulatory blood pressure monitoring ( ABPM ; AND TM2430 , AND , Japan ) - Echocardiography - Arterial property assessment - Six minute walk test ( 6MWT ) - Cardiopulmonary Exercise Test ( CPET ) subgroup subject - Polysomnography portable device - Pulmonary function test ( sea level baseline visit ) - Fluid balance chart - Blood urine analysis : Visit 1 : electrolyte , creatinine , estimate glomerular filtration rate ( eGFR ) , glycemia , renin , angiotensin , aldosterone , plasma catecholamine , 24 h urinary sodium excretion , carbonic anhydrase activity isoenzyme expression ( 50 randomly select subject ) , sample genetic study . Visit 2 : electrolyte , creatinine , eGFR . Visit 3 : complete blood count , electrolytes , creatinine , eGFR , glycemia , insulin , renin , angiotensin , aldosterone , plasma catecholamine , classic urinalysis , microalbuminuria , 24 h urinary sodium excretion , carbonic anhydrase activity isoenzyme expression ( 50 subject select Visit 1 ) . Visit 4 : electrolyte , creatinine , eGFR , glycemia , insulin , renin , angiotensin , aldosterone , plasma catecholamine , 24 h urinary sodium excretion , carbonic anhydrase activity isoenzyme expression ( 50 subject select Visit 1 )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Altitude Sickness</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Permanent residence low ( &lt; 500 ) altitude Conventional systolic BP ( average two measurement ) 140159 mmHg conventional diastolic BP 9099 mmHg subject untreated 4 week washout Mean daytime systolic BP ≥135 &lt; 150 mmHg and/or mean daytime diastolic BP ≥85 &lt; 95 mmHg subject untreated 4 week washout Written inform consent participate study Conventional systolic BP ( average two measurement ) ≥150 mmHg conventional diastolic BP ≥95 mmHg treat subject Regular use two antihypertensive drug ( exception subject two antihypertensive drug low dos ) Treated antihypertensive subject withdrawal treatment deem unethical investigator ( e.g . existence compel indication hypertension continuous use previously use antihypertensive agent ) Contraindications ( include history adverse reaction ) angiotensin receptor blocker calcium antagonist History serious mountain sickness Subjects 3 month precede inclusion study spend considerable ( &gt; 1 week ) amount time altitude 2500 m. Cardiovascular diseases hypertension ( coronary heart disease , heart failure , atrial fibrillation , valvular congenital heart disease , cardiomyopathy , cerebrovascular disease , peripheral artery disease , aortic aneurysm ) Suspected confirmed secondary hypertension Diabetes mellitus Serious respiratory disorder Other condition deem relevant investigator ( include liver disease , renal disease , thyroid disorder ) BMI ≥35 kg/m2 Upper arm circumference &gt; 32 cm know severe obstructive sleep apnea ( apneahypopnea index &gt; 30 use CPAP ) excessive daytime sleepiness ( Epworth Sleepiness Scale &gt; 10 ) Pregnancy Premenopausal woman use effective contraceptive method Elevated probability noncompliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>arterial hypertension</keyword>
	<keyword>high altitude</keyword>
	<keyword>hypobaric hypoxia</keyword>
	<keyword>combination treatment</keyword>
	<keyword>angiotensin receptor blocker</keyword>
	<keyword>calcium antagonist</keyword>
</DOC>